Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017342 · ClinicalTrials.gov registry record · Phase 2
Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia
A Phase 2 study of Leukemia, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Study locations
NCT00017342 is a Phase 2 study of Leukemia that has completed, run by Virginia Commonwealth University. The trial reports 4 study locations across 3 states.
The verdict
NCT00017342, a Phase 2 study of Leukemia, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining bryostatin 1 with cytarabine in treating patients who have relapsed primary acute myelogenous leukemia.
Conditions Studied
Interventions
- DRUG cytarabine
- DRUG bryostatin 1
Study Locations (4)
New York
- New York Weill Cornell Cancer Center at Cornell University - New York
- Herbert Irving Comprehensive Cancer Center at Columbia University - New York
Texas
- University of Texas - MD Anderson Cancer Center - Houston
Virginia
- Massey Cancer Center at Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00017342
The ClinicalTrials.gov registry entry for NCT00017342 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 2 interventions - of which cytarabine is the first listed.
NCT00017342 reports 4 study locations spanning 3 distinct geographic areas - top geographies include New York, Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT00017342 about?
NCT00017342 is a clinical study titled "Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining bryostatin 1 with cytarabine in treating patients who hav...
What is the current status of trial NCT00017342?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-07. Estimated completion is 2005-06.
What conditions does trial NCT00017342 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00017342?
The interventions under investigation include: cytarabine (DRUG), bryostatin 1 (DRUG).
Who is sponsoring clinical trial NCT00017342?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00017342 being conducted?
This trial has 4 study locations across New York, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.